摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

benzylphosphinic acid | 20394-86-9

中文名称
——
中文别名
——
英文名称
benzylphosphinic acid
英文别名
benzylphosphonous acid;phenyl-methyl-phosphinic acid
benzylphosphinic acid化学式
CAS
20394-86-9
化学式
C7H9O2P
mdl
——
分子量
156.121
InChiKey
PHIBEYMUALDAQI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.4
  • 重原子数:
    10
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.14
  • 拓扑面积:
    37.3
  • 氢给体数:
    1
  • 氢受体数:
    2

SDS

SDS:a6ece225b28801b83f69f589d015e2bb
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    benzylphosphinic acid 在 5percent Pd/C 氢气 、 sodium hydride 、 N,N'-二环己基碳二亚胺 作用下, 以 四氢呋喃乙醇二氯甲烷 为溶剂, 20.0 ℃ 、344.75 kPa 条件下, 反应 36.0h, 生成 2-[[(phenylmethyl)hydroxyphosphinyl]methyl]pentanedioic acid
    参考文献:
    名称:
    Design and Pharmacological Activity of Phosphinic Acid Based NAALADase Inhibitors
    摘要:
    A novel series of phosphinic acid based inhibitors of the neuropeptidase NAALADase are described in this work. This series of compounds is the most potent series of inhibitors of the enzyme described to date. In addition, we have shown that these compounds are protective in animal models of neurodegeneration. Compound 34 significantly prevented neurodegeneration in a middle cerebral artery occlusion model of cerebral ischemia. In addition, in the chronic constrictive mc del of neuropathic pain, compound 34 significantly attenuated the hypersensitivity observed with saline-treated animals. These data suggest that NAALADase inhibition may provide a new approach for the treatment of both neurodegenerative disorders and peripheral neuropathies.
    DOI:
    10.1021/jm0001774
  • 作为产物:
    描述:
    氯化苄tris(dibenzylideneacetone)dipalladium(0) chloroform complex 、 Aniline phosphinate 、 三乙胺4,5-双二苯基膦-9,9-二甲基氧杂蒽 、 sodium hydroxide 、 盐酸 作用下, 以 四氢呋喃乙醚 为溶剂, 以69%的产率得到benzylphosphinic acid
    参考文献:
    名称:
    单芳基和二芳基次膦酸的高效合成:微波辅助钯催化的芳基卤化物与次膦酸酯的交叉偶联
    摘要:
    开发了一种通用有效的方法,以Pd(0)和Xantphos为辅助配体,由苯磺酸次膦酸和芳基卤化物微波辅助合成单和二芳基次膦酸。
    DOI:
    10.1016/j.tet.2009.10.028
  • 作为试剂:
    描述:
    diethoxymethyl(benzyl)phosphinic acid ethyl ester氯甲酸乙酯hexane-diethyl etherSodium sulfate-IIIbenzylphosphinic acid二氯甲烷三乙胺 、 crude product 作用下, 以 盐酸二氯甲烷 为溶剂, 5.0~100.0 ℃ 、66.66 Pa 条件下, 反应 23.5h, 以yielding benzylphosphinic acid ethyl ester having a boiling point of 96°100° (5×10-6 bar)的产率得到ethyl benzyl-H-phosphinate
    参考文献:
    名称:
    N-substituted aminoalkanephosphinic acid derivatives, compositions
    摘要:
    具有GABA.sub.B-拮抗作用的化合物,例如式I的化合物##STR1## 其中R.sub.1,R.sub.2和R.sub.3中的一个是氢或脂肪族,环脂肪族,芳基脂肪族或芳香族基,另一个是氢或,在R.sub.1或R.sub.2的情况下,羟基或,在R.sub.1的情况下,卤素或,在R.sub.2与R.sub.2'的情况下,是氧代,其余基团是氢,R.sub.1'是氢或卤素,R.sub.2'是氢,羟基或与R.sub.2一起是氧代,R.sub.4和R.sub.5是氢或R.sub.4是芳基脂肪族或杂环芳基脂肪族基,R.sub.5是氢或脂肪族基,R是至少具有2个碳原子的脂肪族,环脂肪族,环脂肪族-脂肪族,芳基脂肪族,杂环芳基脂肪族或芳香族基,当R.sub.1为氢或羟基时,R.sub.2是芳基基团,R.sub.1',R.sub.2'和R.sub.3为氢。其中R为甲基,以及它们的药学上可接受的盐,可用作治疗“小发作”型癫痫的药物的活性成分。本发明还涉及式I的新化合物及其制备方法。
    公开号:
    US05545631A1
点击查看最新优质反应信息

文献信息

  • [EN] AMINOPEPTIDASE A INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME<br/>[FR] INHIBITEURS D'AMINOPEPTIDASE A ET COMPOSITIONS PHARMACEUTIQUES LES COMPRENANT
    申请人:QUANTUM GENOMICS
    公开号:WO2020084131A1
    公开(公告)日:2020-04-30
    The present invention relates to a novel compound, to a composition comprising the same, to methods for preparing the compound, and the use of this compound in therapy. In particular, the present invention relates to compound that is useful in the treatment and prevention of primary and secondary arterial hypertension, ictus, myocardial ischaemia, cardiac and renal insufficiency, myocardial infarction, peripheral vascular disease, diabetic proteinuria, Syndrome X and glaucoma.
    本发明涉及一种新型化合物,包括该化合物的组合物,制备该化合物的方法,以及该化合物在治疗中的应用。具体而言,本发明涉及一种在治疗和预防原发性和继发性动脉高血压、中风、心肌缺血、心脏和肾功能不全、心肌梗死、外周血管疾病、糖尿病蛋白尿、X综合征和青光眼中有用的化合物。
  • Certain N-substituted-amino-alkane phosphinic acid derivatives having
    申请人:Ciba-Geigy Corporation
    公开号:US05229379A1
    公开(公告)日:1993-07-20
    Compounds having GABA.sub.B -antagonistic properties, for example those of formula I ##STR1## wherein one of the radicals R.sub.1, R.sub.2 and R.sub.3 is hydrogen or an aliphatic, cycloaliphatic, araliphatic or aromatic radical, another is hydrogen or, in the case of R.sub.1 or R.sub.2, hydroxy or, in the case of R.sub.1, halogen or, in the case of R.sub.2 together with R.sub.2 ', oxo, and the remaining radical is hydrogen, R.sub.1 ' is hydrogen or halogen, R.sub.2 ' is hydrogen, hydroxy or, together with R.sub.2, is oxo, R.sub.4 and R.sub.5 are hydrogen or R.sub.4 is an araliphatic or heteroarylaliphatic radical and R.sub.5 is hydrogen or an aliphatic radical, and R is an aliphatic, cycloaliphatic, cycloaliphatic-aliphatic, araliphatic, heteroarylaliphatic or aromatic radical having at least 2 carbon atoms or, when R.sub.1 is hydrogen or hydroxy, R.sub.2 is an aromatic radical and R.sub.1 ', R.sub.2 ' and R.sub.3 are hydrogen, R is methyl, and their pharmaceutically acceptable salts, can be used as active ingredients in medicaments for the treatment of epilepsies of the "petit mal" type. The invention relates also to novel compounds of formula I and processes for the preparation thereof.
    具有GABA.sub.B-拮抗性质的化合物,例如具有以下式I的化合物##STR1##其中R.sub.1、R.sub.2和R.sub.3中的一个是氢或脂肪族、环脂族、芳基脂肪族或芳香族基团,另一个是氢或在R.sub.1或R.sub.2的情况下是羟基或在R.sub.1的情况下是卤素或在R.sub.2与R.sub.2'一起是氧代基,其余基团是氢,R.sub.1'是氢或卤素,R.sub.2'是氢、羟基或与R.sub.2一起是氧代基,R.sub.4和R.sub.5是氢或R.sub.4是芳基脂肪族或杂环芳基脂肪族基团,R.sub.5是氢或脂肪族基团,R是至少有2个碳原子的脂肪族、环脂族、环脂族-脂肪族、芳基脂肪族、杂环芳基脂肪族或芳香族基团,当R.sub.1是氢或羟基时,R.sub.2是芳香族基团,且R.sub.1'、R.sub.2'和R.sub.3是氢时,R是甲基,以及它们的药学上可接受的盐,可用作治疗“小发作”型癫痫的药物中的活性成分。该发明还涉及具有式I的新化合物以及其制备方法。
  • Rapid and Efficient Synthesis of Unsymmetrical Phosphinic Acids R′P(O)OHR″
    作者:Cécile Fougère、Erwann Guénin、Julie Hardouin、Marc Lecouvey
    DOI:10.1002/ejoc.200900852
    日期:2009.12
    A new synthesis of unsymmetrical phosphinic acids R′P(O)OHR″ has been evaluated. The first P–C bond was formed by base-promoted H-phosphinate alkylation of a protected H-phosphinate, which is easier and safer to handle. A one-pot methodology was developed for the second P–C bond formation reaction that involves the sila-Arbuzov reaction. This methodology was then extended to the synthesis of a dialkylphosphinic
    已经评估了不对称次膦酸 R'P(O)OHR" 的新合成。第一个 P-C 键是由受保护的 H-次膦酸盐的碱促进 H-次膦酸盐烷基化形成的,处理起来更容易、更安全。为涉及 sila-Arbuzov 反应的第二个 P-C 键形成反应开发了一种一锅法。然后将该方法扩展到具有基官能团的二烷基次膦酸的合成。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2009)
  • Synthesis of alkyl phosphinic acids from silyl phosphonites and alkyl halides
    作者:E.Andrew Boyd、Andrew C. Regan、Keith James
    DOI:10.1016/s0040-4039(00)73157-1
    日期:1994.6
    Mono- and di-substituted phosphinic acids have been synthesised in a one-pot reaction, by the addition of alkyl halides to silyl phosphonites, under mild and flexible conditions.
    通过在温和而灵活的条件下,将烷基卤加入甲硅烷亚膦酸酯中,通过一锅法反应合成了单取代和二取代的次膦酸
  • Recent advances in phosphorus–carbon bond formation: synthesis of H-phosphinic acid derivatives from hypophosphorous compounds
    作者:Jean-Luc Montchamp
    DOI:10.1016/j.jorganchem.2004.10.005
    日期:2005.5
    This account summarizes the research conducted in our laboratory over the past five years. New methodologies were devised for the formation of P–C bonds with a focus on the reactions of hypophosphorous acid derivatives. Three types of reactions have been developed: palladium-catalyzed cross-coupling, room-temperature radical addition, and palladium-catalyzed addition. Our results are summarized in
    该报告总结了过去五年来我们实验室进行的研究。设计了新的方法来形成P-C键,重点是次磷酸生物的反应。已经开发出三种类型的反应:催化的交叉偶联,室温自由基加成和催化的加成。我们在所有这些领域中总结了我们的结果,其中包括一些我们的最新数据。(1)我们的催化交叉偶联已扩展到烷基次膦酸酯与各种芳基,杂芳基甚至烯基亲电试剂的直接偶联。(2)在自由基条件下添加次磷酸从烯烃延伸至炔烃
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫